Clinical Trial: A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07889245) titled 'A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.' on Oct. 13.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial evaluating the efficacy and safety of FXR0906 in patients with severe hypertriglyceridemia or hypertriglyceridemia with atherosclerotic cardiovascular disease (diagnosed or at increased risk).

Study Start Date: Oct. 23

Study Type: INTERVENTIONAL

Condition: sHTG HTG With ASCVD (Diagnosed or at Increased Risk)

Intervention: DRUG: FXR0906 injection

2 doses of FXR0906 (dose 1 ) by subcutaneous (sc) injec...